EYPT · EyePoint, Inc.
$12.47
-1.50% last session
End-of-day data · updated 2026-07-25
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-4.0
Dividend yield
—
Beta
1.74
Avg volume
1M
Employees
0K
2D change
-2.25%
5D change
-3.71%
10D change
-11.99%
30D change
-11.09%
60D change
-8.69%
MTD change
-7.65%
YTD change
-33.28%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — EYPT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-16
Latest call per bank · past 12 months
RBC Capital
Outperform$37.00
+196.7% vs priceCitigroup
Buy$35.00
+180.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-16 | Stifel | Initiates | Buy | $0.00 → $40.00 |
| 2026-07-01 | Chardan Capital | Maintains | Buy | $29.00 → $65.00 |
| 2026-06-24 | Guggenheim | Reiterates | Buy | $68.00 |
| 2026-05-07 | RBC Capital | Maintains | Outperform | $39.00 → $37.00 |
| 2026-03-09 | Citigroup | Maintains | Buy | $31.00 → $35.00 |
| 2026-03-05 | HC Wainwright & Co. | Maintains | Buy | $23.00 → $30.00 |
| 2026-03-04 | Chardan Capital | Maintains | Buy | $27.00 → $29.00 |
| 2025-11-06 | RBC Capital | Maintains | Outperform | $28.00 → $39.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 41 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.5% below the 50-day MA ($13.19).
- Price vs 200-day MA: Trading 11.8% below the 200-day MA ($14.13).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.21) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($9.71) and high ($18.85).
EYPT Price Chart
Loading chart for EYPT…
Fundamentals
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.